Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]
Menon R, David BG. Clinical, Cosmetic and Investigational Dermatology. 2015;8:215–22.
On page 215, please note correspondence should have been listed as:
Roshni Menon, D II/17,
JIPMER Campus, Dhanvanthri Nagar,
Pondicherry, India 605006
Tel +91 944 320 8140
Email [email protected]
On page 215, the first sentence of the Introduction was “Psoriasis is a chronic inflammatory disease of the skin characterized by exacerbations and remissions affecting 1%–3% of the world’s population, and approximately 20% of patients have moderate to severe disease.1,2” however should have been “Psoriasis is a chronic inflammatory disease of the skin characterized by exacerbations and remissions affecting 1%–3% of the world’s population. Approximately 20% of patients have moderate to severe disease.1,2”
On page 217, 219, and 221 the running header was “Itolizumab – aCD6 monoclonal antibody for the treatment of psoriasis” however should have been “Itolizumab – a humanized anti CD6 monoclonal antibody for the treatment of psoriasis”.
On page 218, Table 1, the second column heading was listed as “Anand et al25 n=40 (moderate–severe psoriasis)” however should have been “Anand et al25 n=40/32 weeks (moderate–severe psoriasis)”.
Read the original article
© 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.